Compare · ABT vs EWTX
ABT vs EWTX
Side-by-side comparison of Abbott Laboratories (ABT) and Edgewise Therapeutics Inc. (EWTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and EWTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.59B, about 38.4x EWTX ($4.76B).
- Over the past year, ABT is down 20.0% and EWTX is up 197.6% - EWTX leads by 217.6 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 7 for EWTX).
- ABT has more recent analyst coverage (25 ratings vs 16 for EWTX).
- Company
- Abbott Laboratories
- Edgewise Therapeutics Inc.
- Price
- $105.58-2.49%
- $43.83+1.66%
- Market cap
- $182.59B
- $4.76B
- 1M return
- -2.07%
- +0.78%
- 1Y return
- -20.02%
- +197.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 16
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest EWTX
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- Amendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael
- Amendment: SEC Form 4 filed by CMO Donovan Joanne M.
- Amendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J
- Amendment: SEC Form 4 filed by General Counsel Moore John R
- Amendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad
- SEC Form 4 filed by Chief Financial Officer Nofi Michael
- General Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)
- CMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)